Abstract. The present study reports on a family with two members affected by Danon disease but having different phenotypes. The clinical manifestations of Danon disease include cardiomyopathy, skeletal myopathy and different degrees of intellectual disability that varies greatly among patients. The present case study reports on two siblings, an older sister and a younger brother, with Danon disease from an affected pedigree, presenting with distinctly different phenotypes. The sister was diagnosed with dilated cardiomyopathy at the age of 26 years with an unfavorable outcome, while her younger brother presented with hypertrophic cardiomyopathy in a relatively stable state. The two probands shared the same mutation, c.974delTinsAA in exon 8, in the lysosomal-associated membrane protein-2 gene. Of note, the two patients had a pre-excitation pattern in the electrocardiogram on initial presentation and later developed atrial fibrillation (AF), which markedly aggravated heart failure. To the best of our knowledge, AF has not been widely reported in patients with Danon disease. The development of AF may have a prognostic value under these circumstances.
Introduction
Danon disease is a rare X-linked disorder clinically characterized by a triad of cardiomyopathy, intellectual impairment and skeletal myopathy (1) . Danon disease is caused by genetic defects in the lysosome-associated membrane protein 2 (LAMP2) gene, which encodes the LAMP2 protein (2) . Cardiac involvement is prominent in patients with Danon disease, while left ventricular hypertrophy and dilation may be present with the former being more prevalent in males (2, 3) . Cardiac symptoms usually occur in adolescence and during the third decade of life, while most patients die from heart failure. Electrical conduction abnormalities are also common, presenting in >3/4 of males and females with Danon disease. Specifically, ventricular pre-excitation is the most common electrocardiographic pattern (3) .
Danon disease is an inherited disease that may be passed on to the next generation. The present study reports on two cases of Danon disease in a single family with distinctly different phenotypes. In this pedigree, three generations involving 6 family members were assessed, including one case of sudden death (Patient I:2), and two cases of cardiomyopathy (Patients II.1 and II.3). Patients II.1 and II.3 developed atrial fibrillation (AF) in the later course of the disease, which is not common. In addition, a literature review was performed by searching PubMed on the aspects of clinical course, phenotype-genotype association, optimal management and prognosis of Danon disease.
Case report
Patient II.1. Patient II.1 was the older child of the family, the history of which comprised sudden cardiac death in the patient's mother of 47 years old and hypertrophic cardiomyopathy (HCM) in the patient's brother (Patient II.3). The pedigree chart is provided in Fig. 1 Fig. 2A) . At nine months later, the patient was admitted due to advanced heart failure with persistent AF (Fig. 2B) . The echocardiographic examination revealed mild left ventricular hypertrophy (interventricular septum, 13 mm; left ventricle anterior wall, 12 mm) and dilated left heart (atrium, 37 mm; left ventricle at end diastole, 63 mm) (Fig. 2C) . The left ventricular systolic function was severely impaired with an ejection fraction of 29% (Fig. 2D ). Biopsy specimens were taken from the patient's left deltoid muscle. NADH enzyme staining indicated that small irregular vacuoles were scattered in certain muscle fibers, and a small amount of type I muscle fiber aggregated in edge particles (Fig. 3C) . ATPase staining revealed clustering in some areas (Fig. 3B) . The pathological diagnosis was myogenic fiber disorder myopathy (Fig. 3) .
For sequence analysis, DNA was extracted from blood. A heterozygous frameshift missing mutation was identified in the LAMP2 gene of the patient. The proband harbored an identical c.974delTinsAA in exon 8 (Fig. 2E) .
Collectively, the patient was admitted to the hospital 6 times for heart failure decompensation within 2 years and experiyears and experiand experienced sudden cardiac death during her last hospitalization at the age of 28 years.
Patient II.3. Patient II.3, the younger brother of Patient II.1, was a 23-year-old male presenting with a distinctly different clinical course and initial manifestation. He was initially referred to a local hospital due to an unexplained elevation of cardiac enzyme in April 2016, one year before his referring to our department, and dyspnea and weakness followed. Clinical examination revealed hepatomegaly with no obvious edema. He reported mild fatigue during physical activity. Abnormalities in laboratory parameters included serum procarbamide transaminase (155 U/l; normal range, 9-50 U/l), serum aspartate aminotransferase (215 U/l; normal range, 15-40 U/l), serum creatine kinase (945 U/l; normal range, 24-194 U/l), serum creatine kinase isoenzyme (45.40 U/l; normal range, 0-24 U/l), serum α-hydroxybutyrate dehydrogenase (711 U/l; normal range, 24-194 U/l) and serum γ-glutamyl transpeptidase (72 U/l; normal range, 10-60 U/l). The chest X-ray revealed mild cardiomegaly. A ventricular pre-excitation pattern was evident in the ECG (Fig. 4A) . The ECG examination revealed interventricular septum hypertrophy of 15 mm and diffuse thickening of the left ventricular wall (Fig. 4C) . The patient had a decreased left ventricular systolic function with an ejection fraction of 37% (Fig. 4D) . Pathological diagnosis was also myogenic fiber disorder myopathy, similar to that in patient II.1 but with more obvious vacuoles in fibers.
DNA sequence analysis was also performed using a sample extracted from an oral swab. An identical mutation to that in patient II.1 was detected; the only difference was in the homozygous presentation.
Over one year, patient II.3 was admitted to the hospital 3 times for heart failure decompensation, while pertinent labotimes for heart failure decompensation, while pertinent labotimes for heart failure decompensation, while pertinent laboratory results and cardiac function estimated by ECG did not indicate any significant alterations. The patient developed AF (Fig. 4B ) during his second hospitalization and ~1 year later his sinus rhythm was restored following catheter radiofrequency ablation. At the time of writing of the manuscript, one year after the intervention, the patient remained in a relatively stable state.
Other family members. Patients I.1 and III.1 had normal psychomotor development and no exercise intolerance. The LAMP2 gene mutation was not identified in these two family members. Patient I.2, the mother of Patient II.1, suffered a sudden cardiac death without an accurate diagnosis. Patient II.2 was normal with no sign of mental or physical disorders.
Discussion
The present study described 2 cases of Danon disease in a single family, which clearly differed in terms of severity of the underlying cardiomyopathy. In previous cases, AF has not been widely described to develop after progression of the disease, as in the two patients of the present study. In the subsequent section, a review of the literature is provided and the epidemiology, manifestations, cardiac electrical abnormalities, imaging examinations and genetics of Danon disease are discussed.
The literature search was performed using PubMed to identify articles and case reports without any time limitation to identify articles and case reports on Danon disease. The search terms were a combination of 'Danon disease', 'lysosomal glycogen storage disease without acid maltase deficiency' and 'glycogen storage disease IIb'. First, the epidemiology of Danon disease was reviewed. Of note, the majority of published data on Danon disease originate from case reports and the prevalence of this disease is undetermined. A recent study reported a prevalence of 1.5% in a cohort with unexplained left ventricular hypertrophy, rising to 30% in patients with unexplained left ventricular hypertrophy and pre-excitation on ECG (4). Almost all patients had the manifestation of cardiomyopathy, with males predominantly presenting with a HCM phenotype, while females presented with HCM or DCM equally (3). It is noteworthy that patients with idiopathic HCM most commonly exhibit preserved systolic function and better prognosis (5) . However, patients with Danon disease presenting with an HCM pattern and manifesting with preserved systolic function early in the course of disease may later progress with a worse prognosis. One study identified LAMP2 mutations in 4 of 64 patients with HCM, while no LAMP2 mutation was detected in 72 patients with DCM (6). In another study of an affected family, contrary to common sense, DCM was predominant in male patients (7) . Of note, the prevalence of diagnosed cases of Danon disease may be rising due to increased detection based on the expanding knowledge of this rare disease.
The clinical features of Danon disease were then reviewed. Danon disease has been increasingly reported, mostly as case reports, during the past few years. To the best of our knowledge, female patients with Danon disease mostly present with mild symptoms and a later onset (13.3±8.0 years of age for male patients and 28.9±14.2 years for female patients; P= 0.0008) (3). Of note, the female patient of the course in female patients with Danon disease may have a broad spectrum. The youngest female patient reported had an onset at the age of 12 years (11) . In addition, a 38-year-old female, whose son was diagnosed with Danon disease based on genetic analysis, harbored the same mutation as her son and was asymptomatic with no specific abnormalities in the ECG, physical examination and blood biochemistry (12) . Regarding the variety and severity of cardiomyopathy symptoms, Hedberg Oldfors et al (13) reported that an uneven distribution of LAMP2 protein causing deleterious effects in the myocardium may have a more significant role than an overall moderate reduction of LAMP2 protein.
Cardiomyopathy is present in almost all patients with Danon disease. Of note, the two probands of the present study did not exhibit any clinical indication of skeletal myopathy or intellectual disability. Due to lack or decrease of LAMP2 protein in all body parts of the patients, certain less prevalent symptoms may also occur. In the eye, LAMP2 is expressed only in the retinal pigment epithelium (14) , and retinal abnormalities are estimated to occur in 64-69% of patients (3) . Hepatic disease has also been described in patients with Danon disease (2,15). Autism associated with Danon disease was reported in a 16-month-old male with normal presentation on cardiac evaluation (16) . All avail- (16) . All avail-(16). All available evidence indicates that Danon disease is a multi-system disease and therefore, attention should be paid to symptoms of systems other than cardiovascular system in order to avoid a missed diagnosis of this lethal disease. Regarding cardiac electrical abnormalities, a ventricular pre-excitation pattern was evident in the patients, but no electrophysiological evaluation was performed. Ventricular pre-excitation is the most frequent abnormality on ECG in this setting and it has been demonstrated in 68% of males and 27% of females (3) . However, in a recent study, pre-excitation was identified in only 11 out of 27 patients with Danon disease (17) . Of note, in a study that performed an electrophysiologic evaluation of 4 male patients with Danon disease and initial QRS complex mimicking ventricular pre-excitation on ECG, no accessory pathway was identified (18) . On the other hand, a fascicu- (18) . On the other hand, a fascicu- (18) . On the other hand, a fasciculoventricular pathway was discovered on electrophysiology examination in a 13-year-old male with Danon disease from Spain in 2008 (19) . These results were consistent with those of a further case (20) . In addition, a recently published study demonstrated that a fasciculoventricular pathway was present in 2 out of 3 patients with Danon disease, with no electropatients with Danon disease, with no electropatients with Danon disease, with no electrophysiology results available in the one remaining patient (4). According to the aforementioned studies focusing on pre-excitation, a fasciculoventricular pathway may represent a hallmark of Danon disease.
The present study provided electrocardiographic evidence of AF in the Patient II. (20) reported on a 14-year-old male diagnosed with Danon disease who presented with persistent palpitations at the age of 8 years. He had Wolff-Parkinson-White syndrome, brief runs of atrial tachycardia and pre-excited AF, and experienced sudden cardiac death at the age of 14. Konrad et al (18) observed AF in 5 out of 7 patients with Danon disease from 3 families and hypothesized that AF may be associated with thromboembolic events in young individuals, which is supported by another three cases reported previously (21) . In the patients of the present study, AF developed and aggravated the heart failure. There are only few reports of AF in Danon disease, and it may indicate a worse prognosis of this disease. Therefore, it is important to pay attention to the development of AF in patients when the diagnosis is already certain. However, whether aggressive treatment of AF in this setting favorably affects the evolution of heart failure remains elusive. Of note, AF ablation in Patient II.3 of the present study effectively restored the sinus rhythm and improved his general condition.
The genetics associated with Danon disease were then reviewed. The LAMP2 c.974delT mutation identified in the cases of the present study is a frameshift mutation in exon 8 of the LAMP2 gene that was first reported by Nishino et al (1) . Genotype-phenotype associations appear to have a significant role in age of onset of Danon disease. Nonsense, frameshift and large deletion/duplication mutations were associated with the earliest age of onset (22) . In the family described in the present study, the mother of Patient II.1 suffered sudden death at the age of 47, respectively, much later than Patient II.1, and not in accordance with the early-onset pattern of a frameshift mutation. Bertini et al (23) reported that the same mutation of the LAMP2 gene resulted in various phenotypes. Although the mutation type significantly affected the phenotype, there are other factors contributing to the final phenotype, which may explain for the heterogeneity of phenotypes. Danon disease is caused by mutation of the LAMP2 gene; however, in a previous study, a patient with normal DNA sequencing results presented with symptoms of Danon disease, and a LAMP2 microduplication was confirmed by PCR and RT-PCR analyses (24) . From the above, it is apparent that genotype-phenotype associations summed up previously may not apply in numerous cases.
Regarding imaging examination and treatment, ECG, particularly three-dimensional speckle-tracking imaging (25) , and cardiac magnetic resonance (26) have a significant role in the diagnosis and assessment of Danon disease, as reported in numerous cases (25, 27) . The final treatment of Danon cardiomyopathy is heart transplantation, while applying a left ventricular assist device at the appropriate time is a crucial management method prior to heart transplantation (28) . Implantation of a cardioverter defibrillator is also a useful treatment, and subcutaneous implantable cardioverter defibrillators have the advantage of terminating ventricular tachycardia or fibrillation much better than transvenous implantable cardioverter defibrillators (29) .
In conclusion, the present study reported on a frameshift mutation in the LAMP2 gene in 2 siblings with cardiomyopathy. For patients with DCM or HCM, elevated serum myocardial enzyme and serum liver enzyme, a pre-excitation in the ECG, fibrosis or dynamic abnormities on ECG examination or cardiac magnetic resonance imaging, retinopathy myopathy and intellectual impairment, particularly with an X-linked family history, point to the diagnosis of Danon disease. Muscle biopsy and genetic mutation analysis are necessary to make a definite diagnosis. The development of AF may represent a significant feature of Danon disease. The prognostic significance of AF and its impact on the management of patients with Danon disease requires further study.
